DSGNDesign Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+11% of shares).
Rangebound, no clear trend. Price is −16% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How DSGN is trading
Design Therapeutics, Inc. is +85% over the past year while the S&P 500 is +16%: 69 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −16%
vs 200-day average · a clear downtrend
- RSI (14)
- 31
RSI (14) · neutral
- Below its 52-week high
- 36%
Below its 52-week high
Details›
- Last close2026-10-23
- $10.23
- 1 monthS&P 500 −0.94%
- −16%
- 1 yearS&P 500 +16%
- +85%
- 5 yearsS&P 500 +86%
- −28%
- vs 50-day average$13.11
- −22%
- 52-week high
- $15.94
- 52-week low
- $5.70
- Annualised volatility
- 82%
| Year | Return |
|---|---|
| 2026 (year to date) | +9.1% |
| 2025 | +52% |
| 2024 | +133% |
| 2023 | −74% |
| 2022 | −52% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 1 of 5 | −18% |
| Feb | 5 | 4 of 5 | +3.4% |
| Mar | 5 | 3 of 5 | +5.4% |
| Apr | 6 | 3 of 6 | +2.4% |
| May | 6 | 2 of 6 | −6.6% |
| Jun | 6 | 3 of 6 | +1.9% |
| Jul | 6 | 4 of 6 | +16% |
| Aug | 6 | 4 of 6 | −0.82% |
| Sep | 6 | 2 of 6 | +0.66% |
| Oct | 6 | 1 of 6 | −7.6% |
| Nov | 5 | 4 of 5 | +14% |
| Dec | 5 | 3 of 5 | +2.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.